Alnylam UK - Alnylam

To those who say “impossible, impractical, unrealistic,” we say adsa:

Challenge Accepted

We are developing an innovative new class of medicines called RNAi therapeutics that we believe have the potential to transform the lives of people living with rare diseases.

AT THE FOREFRONT OF CHANGE

Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including five product candidates that are in late-stage development and three products approved in the U.S and the European Union.

>1k

Employees

Countries

Programmes Currently in Clinical Development

Approved Products

>35

Clinical Studies to Date

Years Longest Duration of Exposure

Updated as of June 2021

RNAi: A REVOLUTION IN BIOLOGY BUILT ON NOBEL PRIZE-WINNING RESEARCH

RNA interference (RNAi) is a breakthrough in understanding how genes are regulated in cells. It also represents a completely new approach to drug discovery and development. The 2006 Nobel Prize for Physiology or Medicine, awarded to Craig Mello and Andrew Fire, recognised the importance of RNAi as a major scientific discovery.

Learn more

DISCOVER HOW
RNAi WORKS

Learn more about RNAi

Learn more about our research, programs, company, culture, patient stories and more.

Visit our YouTube channel

David, living with Hereditary ATTR (hATTR) amyloidosis

Interference RNA (RNAi) – Eureka Moment

OUR FOCUS

Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall under 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

Our products approved for patients in the European Union treat hereditary ATTR (hATTR) amyloidosis with polyneuropathy, acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1). Our therapeutic product candidates in late-stage (Phase 2 – Phase 3) development focus on hereditary ATTR (hATTR) amyloidosis, haemophilia and rare bleeding disorders, hypercholesterolaemia and complement-mediated diseases. We have a number of early-stage programmes in development.

See our pipeline

JOIN OUR TEAM

As we pursue our goal of becoming a commercial organization that can independently deliver medicines to patients, we are seeking individuals with diverse skills, experiences, and backgrounds to help us build a world-class team. We are based in Cambridge, USA, with offices in Zug, Switzerland, and Maidenhead, UK, but we are also hiring throughout Europe.

View current job openings